PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States -…

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that BESREMi (ropeginterferon alfa-2b-njft) is now commercially available in the U.S. to eligible patients with polycythemia vera (PV). BESREMi was approved by the FDA in November as the only interferon for adults with polycythemia vera

Read more
Awards and Honors: Winter 2021 | Department of Medicine News | Stanford Medicine – Stanford Medicine

Department of Medicine Faculty and Staff Named 2021 ISP Award Winners Many projects have been recognized as part of Stanford Medicines Integrated Strategic Plan (ISP), and the ISP Awards highlight individualsand teamsfrom the Stanford Medicine community who, through their extraordinary efforts, embody the strategic priorities of our Integrated Strategic Plan (ISP): Value Focused, Digitally Driven, and Uniquely Stanford.

Read more
Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 – Benzinga

The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.com's offering. The Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Read more
Certain Patients With Heart Failure May Benefit From Stem Cell Therapy – Pharmacy Times

Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Associations Scientific Sessions 2021. The investigators found this improvement was especially pronounced among patients who had higher levels of inflammation. The rate of hospitalization was not reduced.

Read more
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update – Yahoo Finance

BURLINGAME, Calif., December 01, 2021--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021

Read more
Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -…

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma. During a Targeted Oncology Case-Based Roundtable event, Saad Zafar Usmani, MD, MBA, chief, Plasma Cell Disorders Program, director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discussed the case of a 51-year-old patients with newly-diagnosed multiple myeloma with 6 peers. USMANI: How do you discuss the prognosis with your patients

Read more